The long-term side effects of GLP-1 drugs are not well-studied, but the press seems to talk about them as if they are—in glowing terms as if their broad adoption is a given and a lifetime attached to the tit of a friendly drug company (with your credit card inserted) is merely a temporary problem.
I think we need to greet this whole class of drugs with skepticism, if for no other reason than they’re being a pharma companies’ wet dream of a product. The incentives to interrupt their rollout don’t exist.
I’m aware of the wide range of benefits, and understand they may end up saving lives. But skepticism is warranted here.
I think we need to greet this whole class of drugs with skepticism, if for no other reason than they’re being a pharma companies’ wet dream of a product. The incentives to interrupt their rollout don’t exist.
I’m aware of the wide range of benefits, and understand they may end up saving lives. But skepticism is warranted here.